FDA And Pharmaxis Agree On Bronchitol SPA
This article was originally published in The Pink Sheet Daily
Executive Summary
Already being tested under an SPA in cystic fibrosis, the inhalation therapy enters Phase III for bronchiectasis in the U.S. and EU.
You may also be interested in...
Pharmaxis To Expedite Bronchitol Phase III Program In Cystic Fibrosis
Pharmaxis preps for pivotal studies of mannitol after Phase II trials showed lung function improvement.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.